<DOC>
	<DOCNO>NCT00629122</DOCNO>
	<brief_summary>Tacrolimus ( Prograf ) belong class medication know calcineurin inhibitor . It maintenance drug use prevent rejection kidney , liver , heart transplant recipient . Calcineurin inhibitor display high pharmacokinetic ( body 's effect drug ) variability necessitate use blood test ensure adequate drug level present maintain effectiveness safety . The amount oral tacrolimus absorb varies patient population study . Tacrolimus metabolize broken elimination liver small intestine via cytochrome P450 ( CYP ) 3A4 , CYP 3A5 , p-glycoprotein enzyme system . Enzyme activity affect several single nucleotide polymorphism ( SNPs ) individual genetic make-up difference expression may contribute variation tacrolimus pharmacokinetics . There number drug-drug interaction concomitantly administer medication increase decrease break tacrolimus . Early transplant time tacrolimus take mouth , alternative route administration sought . Although intravenous ( vein ) product available , toxic kidney associate allergic reaction . Studies lung transplant recipient utilized sublingual ( tongue ) tacrolimus administration successful outcomes . Drug delivery via oral mucosa alternative method systemic drug administration offer alternative oral administration impractical ( gastrointestinal dysmotility , reduce drug absorption , intestinal failure , difficulty swallowing , nausea vomit ) . Administration tacrolimus sublingual route allow direct entry systemic circulation bypass problem associate drug absorption breakdown take place small intestine . In order learn possible role sublingual tacrolimus among transplant recipient administer tacrolimus sublingually . In addition , evaluate difference expression bioactivity SNP polymorphism effect tacrolimus pharmacokinetics . Patients await kidney transplantation list kidney transplant wait list upcoming live donor transplant center administer five dos sublingual tacrolimus follow five dos oral tacrolimus . We evaluate compare pharmacokinetic characteristic sublingual oral tacrolimus administration among study participant . The purpose study assess pharmacokinetic pharmacodynamic parameter tacrolimus sublingual oral administration . A secondary objective ass drug-drug interaction concomitant therapy clotrimazole .</brief_summary>
	<brief_title>Pharmacokinetics Sublingual Versus Oral Tacrolimus Patients Awaiting Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<criteria>Adult patient await kidney transplantation age â‰¥ 18 year Patients concurrently treat medication interact tacrolimus ( clotrimazole )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Tacrolimus ( Prograf )</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sublingual administration</keyword>
	<keyword>Drug interaction ( Cytochrome P450 p-glycoprotein )</keyword>
</DOC>